Comparative Pharmacology
Head-to-head clinical analysis: GONITRO versus ISMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONITRO versus ISMO.
GONITRO vs ISMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing cGMP levels, leading to smooth muscle relaxation and vasodilation.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
None Documented
None Documented
Clinical Note
moderateVismodegib + Digoxin
"Vismodegib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateVismodegib + Digitoxin
"Vismodegib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateVismodegib + Deslanoside
"Vismodegib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateVismodegib + Acetyldigitoxin
"Vismodegib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator